Introduction
Rotavirus is an important cause of severe gastroenteritis, causing illness and death in young children and in other species (Kapikian & Chanock, 1990) . The worldwide impact of this disease has led to efforts to control infection by the development of oral vaccines (Kapikian & Chanock, 1990 ; Hoshino & Kapikian, 1994) . Several heterologous, homologous and animal\human reassortant attenuated oral rotavirus vaccines have been assessed in infants, but with variable results or deficiencies in aspects of safety, immunogenicity, or efficacy (Vesikari, 1993 ; Rennels et al., 1995 Rennels et al., , 1996 Perez-Schael et al., 1997) . The variable responses to rotavirus vaccines underscore neutralizing antibody titres of serum or intestinal contents, but a positive correlation existed between protection and serum IgA, intestinal IgA and intestinal IgG antibody titres. These findings suggest that serum IgA antibodies to HRV could act as an indicator of IgA antibodies in the intestine after rotavirus infection. The virulent HRV elicited protective immunity and higher levels of serum and intestinal IgA antibodies to HRV compared to attenuated and inactivated HRV. These findings suggest that more efficient mucosal delivery systems and/or adjuvants are needed to enhance the intestinal immune responses to attenuated or inactivated HRV if more successful vaccination is to be achieved in neonates.
the need for a better understanding of the host immune responses and the immunological mechanisms involved in protection of infants (Johansen et al., 1994 ; Rennels, 1997 ; Vesikari, 1997 ; Desselberger, 1998) .
The immunological correlates of protection against natural infection by rotaviruses are not well-established and the role of circulating or intestinal antibodies remains unclear (Johansen et al., 1994 ; Offit, 1994) . Human rotaviruses (HRV) infect the enterocytes of the small intestine, inducing villous atrophy and malabsorptive diarrhoea (Davidson & Barnes, 1979) . Intestinal antibodies are important for the protection of young animals against rotavirus (Offit & Clarke, 1985 ; Snodgrass & Wells, 1978 ; Saif & Jackwood, 1990 ; Coulson et al., 1992 ; Saif et al., 1996 Saif et al., , 1997 suggesting that highly effective rotavirus vaccines must induce local intestinal immunity (Kapikian & Chanock, 1990 ; Saif & Jackwood, 1990 ; Conner et al., 1994 ; Saif et al., 1996 ; Yuan et al., 1996 Yuan et al., , 1998 .
Because of limitations in studying HRV in the natural host (infants and young children), several animal models (mice, 0001-5460 # 1998 SGM CGGB rabbits, calves and pigs) have been developed (Mebus et al., 1977 ; Wyatt et al., 1979 Wyatt et al., , 1980 Ramig, 1988 ; Conner et al., 1991 ; Schaller et al., 1992 ; Hoshino et al., 1995 ; Saif et al., 1996 Saif et al., , 1997 Ward et al., 1996 b ; Yuan et al., 1996 Yuan et al., , 1998 . However, only in gnotobiotic (Gn) calves and pigs does HRV induce both disease and pathology (Mebus et al., 1977 ; Ward et al., 1996 b) . The Gn pig model was used by us to investigate the mucosal and systemic immune responses to rotavirus (Chen et al., 1995 ; Saif et al., 1996 Saif et al., , 1997 Ward et al., 1996 a, b ; Yuan et al., 1996 Yuan et al., , 1998 . We found that the magnitude of the intestinal HRV-specific T-cell response (Ward et al., 1996 a) and the number of intestinal HRV-specific IgA antibody-secreting cells (ASC) (Yuan et al., 1996 (Yuan et al., , 1998 induced by Wa HRV correlated with the degree of protection against virulent HRV challenge ( Saif et al., 1996) . Recent studies of active immunity indicate that parenteral inoculation of mice and rabbits with inactivated rotavirus or rotavirus-like particles generated at least partial protection against rotavirus shedding (Conner et al., 1993 (Conner et al., , 1994 McNeal et al., 1992 ; Coffin et al., 1995) . These results suggest that the use of such non-replicating rotavirus vaccines may offer alternative approaches for immunization against rotavirus. Thus, delineating the mucosal immune responses and identifying the correlates of protective immunity to HRV in Gn pigs may enable researchers to define similar correlates of protective immunity in infants and to develop more effective vaccination strategies.
In the present study, we compared the ability of live (attenuated and virulent) and inactivated HRV to induce protective immunity in Gn pigs against the homologous virulent HRV. We evaluated the time-course, isotype and magnitude of the serum and intestinal antibody responses in these pigs to assess their correlation with protection against challenge.
Methods
Cells and human rotaviruses. The MA104 monkey kidney cell line used for propagation of HRV was maintained in minimal Eagle's medium (MEM ; Gibco Life Technologies) containing antibiotics and 5 % foetal calf serum (Gibco Life Technologies). The cloned cell cultureadapted Wa (P1A[8]G1) HRV (passage 27) was used as the attenuated HRV inoculum and as the antigen in ELISA. The virulent Wa HRV was serially passaged as intestinal contents in Gn pigs (Wyatt et al., 1980 ; Saif et al., 1996 ; Ward et al., 1996 b) . Virus infectivity was determined by a cell culture immunofluorescence (CCIF) assay in MA104 cells (Bohl et al., 1984) . The CCIF titres of the virulent and attenuated HRV were 3n9i10' and 5n4i10( focus-forming units (f.f.u.) per ml, respectively. The attenuated Wa HRV was inactivated with binary ethylenimine (BEI) as described and inactivation was verified by loss of infectivity for MA104 cells (Fernandez et al., 1996) . The antigenicity of the inactivated HRV was confirmed by reactivity with VP4 and VP7 monoclonal antibodies (MAbs) and polyclonal antibodies to rotavirus (Fernandez et al., 1996) .
Inoculation and challenge of Gn pigs.
Pigs were derived and maintained in sterile isolation units (Meyer et al., 1964) . Before oral inoculation, pigs were fed sodium bicarbonate to reduce gastric acidity (Graham, 1987) . At 3-5 days of age, 51 Gn pigs were perorally (PO) inoculated with 2i10( f.f.u. of attenuated Wa HRV (group 1) ; 43 Gn pigs were PO inoculated with 10& f.f.u. (10& ID &! ) of virulent Wa HRV (group 2) ; 17 pigs were PO inoculated with BEI-inactivated Wa HRV (4n5i10( f.f.u. before inactivation) (group 3) ; and 20 pigs were intramuscularly (IM) inoculated with BEI-inactivated Wa HRV in an equal volume of incomplete Freund's adjuvant (group 4). Pigs in groups 1, 3 and 4 were inoculated 10 days later by the same routes with the same virus doses. Seventeen control pigs were sham-inoculated (PO or IM) with equal volumes of diluent (group 5). At post-inoculation day (PID) 21, pigs from each group were challenged PO with 10' f.f.u. of virulent Wa HRV. Nine age-matched Gn pigs were mock-inoculated and mockchallenged as mock controls (group 6). All pigs were examined daily and their faecal consistency was scored as follows : 0, normal ; 1, pasty ; 2, semi-liquid ; and 3, liquid. The mean cumulative faecal score for each group was calculated as the sum of faecal scores for 1 week postchallenge divided by the number of pigs in the group. Rectal swabs (RS) were collected every other day after inoculation and every day postchallenge. Pigs were bled at inoculation and weekly thereafter. Selected pigs from each group (n l 4-13) were euthanized at PID 0, 7-8, 19-21, 25 and 28 [post-challenge days (PCD) k21, k13, 0, 4 and 7] and the large and small intestinal contents (LIC and SIC, respectively) were collected. All sera, RS, LIC and SIC samples were stored at k20 mC until assayed.
CCIF assay. The RS specimens were processed and assayed for rotavirus by the CCIF assay (Bohl et al., 1984) . Briefly, RS fluids were diluted up to 1 : 100 in MEM, then serially diluted (10-fold) and assayed in duplicate in MA104 cell monolayers in 96-well plates (Corning Glass Works). Plates were incubated at 37 mC for 18 h with 5 % CO # before acetone fixation and fluorescent antibody staining. Fluorescing cells were enumerated by fluorescent microscopy and virus titres were expressed as f.f.u. per ml.
Antigen-capture ELISA. An antigen-capture sandwich ELISA using hyperimmune antiserum to group A rotavirus was used to detect Wa HRV antigen in RS fluids (Saif et al., 1983) . Intestinal contents from sham-inoculated Gn pigs were used as negative controls and group A HRV-positive intestinal contents served as positive controls. A sample was positive if the mean absorbance of replicates was greater than the mean absorbance of the negative controls plus 3 SD.
Fluorescent focus reduction virus neutralization (FFN)
assay. Virus neutralizing (VN) antibody titres to the cell culture-adapted Wa HRV were determined by testing serial 2-fold dilutions of serum, LIC or SIC (initial dilution of 1 : 4) in the FFN assay (Kang et al., 1989) . The VN antibody titre was expressed as the reciprocal of the highest dilution of the sample that reduced the number of fluorescent foci by 100 %.
Antibody isotype ELISA. An indirect antibody isotype ELISA similar to that described previously (Fernandez et al., 1996) was used to determine isotype-specific antibody titres to Wa HRV in the serum, LIC and SIC samples. Briefly, 96-well microtitre plates (Nunc-Immuno) were coated with hyperimmune guinea-pig anti-rotavirus serum, blocked with 1n5% (w\v) commercial non-fat dry milk, and semi-purified HRV or mock-infected MA104 cell culture control lysates were added. Plates were washed with PBS-Tween between addition of samples and reagents. All samples\reagents were added in 100 µl volumes to antigen-coated and control wells in the following sequence : serial 4-fold dilutions of each test sample (starting at 1 : 16) ; biotinylated MAbs (from ascites) against porcine IgG, IgA and IgM (dilutions of 1 : 30 000, 1 : 15 000 and 1 : 5000, respectively) (Paul et al., 1989) ; horseradish peroxidase-conjugated streptavidin (KPL) ; and 0n05 % ABTS [2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonate)] substrate. The absorbances (A %"% ) were read using an ELISA reader (Flow Titretek Multiskan ; Flow Laboratories) and titres Immunity to human rotavirus in gnotobiotic pigs Immunity to human rotavirus in gnotobiotic pigs with BEI-inactivated Wa HRV (2 doses, 10 days apart) ; controls were sham-inoculated with diluent and challenged (group 5) or mock-challenged (group 6). Incomplete Freund's adjuvant was used with the IM inoculation. All pigs in groups 1-5 were challenged with virulent Wa HRV (" 10' f.f.u.). These data have been presented in part by Yuan et al. (1996 Yuan et al. ( , 1998 and Ward et al. (1996 a) . † Virus shedding determined by cell culture immunofluorescent infectivity assay or ELISA. ‡ Pigs were positive for diarrhoea if daily faecal consistency score was 2 during the first week post-challenge. Faecal consistency was scored daily as follows : 0, normal ; 1, pasty ; 2, semi-liquid ; and 3, liquid. Mean cumulative score was Σ(faecal scores for 1 week post-challenge)\n. § Before challenge, pigs inoculated with inactivated Wa HRV did not become ill (similar to diluent-inoculated control pigs). For clarity, these data are not included in this table.
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were expressed as the reciprocal of the highest sample dilution in which the mean A %"% of virus-coated wells was greater than the mean A %"% of negative controlsj(3 SD). Titres of 16 were assigned a value of 8 for calculation of geometric mean titre (GMT).
Statistical analysis. Kruskal-Wallis non-parametric analysis of variance was used to identify differences in virus shedding and diarrhoea between treatment groups ; the Wilcoxon-Mann-Whitney non-parametric test was then used to identify pairs of treatments that differed significantly. Significant differences between groups in antibody GMT in each sample type at each time-point were determined by Student's t-test. Significant differences within a group in antibody titres for each sample at different time-points were determined by two-way analysis of variance with the statistical analysis systems (SAS Institute). One-way analysis of variance was used to determine if serum and intestinal VN antibody GMT differed between groups. The rate ratio (RR) and Fisher's Exact test were used to determine whether protection was conferred by treatment. The correlation between isotype-specific antibody responses at challenge (PCD 0) and protection from challenge was established by Spearman's measure of correlation (rho, ρ). Statistical significance was assessed at P 0n05.
Results

Clinical signs and protection following inoculation and challenge
Clinical signs in each group following virus inoculation and challenge are summarized in Table 1 . After inoculation, 6 % of group 1 pigs (attenuated HRV, PO inoculated) shed virus and 12 % developed diarrhoea, whereas 100 % of group 2 pigs (virulent HRV, PO) shed virus and 95 % developed diarrhoea. In comparison, following challenge, 83 % of group 1 pigs shed virus and 61 % developed diarrhoea compared to no virus shedding and 12 % diarrhoea for group 2. Fewer group 1 pigs developed diarrhoea compared to group 5 diluent controls after challenge (61 % vs 88 %), and both the diarrhoea severity (mean cumulative score) and duration were significantly higher for the groups of challenged controls compared to group 1 pigs. The percentage of group 2 pigs with diarrhoea, the mean duration and the diarrhoea severity post-challenge were similar to the mock-challenged (group 6) controls and significantly less than the susceptible challenged controls (group 5).
After inoculation of pigs (groups 3 and 4) either PO or IM with inactivated HRV, no significant diarrhoea or virus shedding occurred. However, after challenge, 88 % of group 3 and 83 % of group 4 developed diarrhoea and all pigs shed virus ( Table 1 ). The duration of diarrhoea of the diluentinoculated, challenged controls (group 5) was longer and the mean cumulative scores higher (but not significantly) than those observed for group 3 and 4 pigs.
Oral inoculation of pigs with virulent Wa HRV conferred a protection rate of 86 % against diarrhoea whereas attenuated Wa HRV conferred a protection rate of 31 %. PO or IM inoculation of pigs with inactivated Wa HRV conferred little or no protection (Table 1 ). The significance of protection conferred by each inoculum was determined by calculating the odds or rate ratios (RRs) of protection from disease (Ward et al., Fig. 1 . Correlation between protection and isotype antibody response at challenge in Gn pigs PO inoculated with attenuated (group 1), virulent (group 2) or inactivated (group 3) virus or IM inoculated with inactivated (group 4) Wa HRV or diluent-inoculated controls (group 5). GMT of serum IgA (#), SIC IgA ( ), and LIC IgG () in each group are shown. Isotypespecific GMT are depicted as log 10 [jconfidence interval (CI) bar] at PID 21 (PCD 0). The ability of the virus inoculum to confer protection against moderate to severe diarrhoea following virulent virus challenge is depicted as the RR value. These were : diluent-inoculated group 5 control pigs, RR l 1 ; virulent Wa HRV group 2, RR l 6n60 (95 % CI, 1n80 RR 24n18) ; live attenuated Wa HRV group 1, RR l 2n92 (95 % CI, 0n71 RR 12) ; inactivated Wa HRV group 4 (IM), RR l 1n25 (95 % CI, 0n21 RR 7n62) ; and inactivated Wa HRV group 3 (PO), RR l 1 (95 % CI, 0n1 RR 8n82). The magnitude of isotype-specific antibody responses at challenge positively correlated with the protection afforded by the inoculum ( ρ l 0n7, 0n8 and 0n9 for SIC IgA, LIC IgG and serum IgA, respectively).
1996 a ; Fig. 1 ). In comparison with diluent alone (RR l 1), inoculation of pigs with virulent (RR l 6n6) and attenuated (RR l 2n9) Wa HRV significantly increased the probability of protection from diarrhoea post-challenge, whereas inoculation with inactivated Wa HRV PO (RR l 1) or IM (RR l 1n3) did not.
Serum and intestinal VN antibody responses
Detailed assessment of serum and intestinal VN antibody GMT after inoculation and challenge are summarized (Table 2 , Fig. 2 ). VN antibodies were not detected in serum or intestinal contents of diluent controls until PCD 7, with the intestinal VN GMTs similar to those of group 3. No significant differences in the VN GMTs were detected among samples or groups at PID 7. The serum VN GMT of group 4 was significantly higher than the serum VN GMTs of groups 1, 2 and 3 at PID 21 as well as at PCD 4 and 7 (Table 2) . No serum VN antibodies were detected in group 1 at PID 7 although 100 % seroconverted by PID 21 (GMT l 40) and all had significantly increased serum VN antibody titres post-challenge. Serum VN antibodies were detectable in 28 % of group 2 pigs at PID 7 (GMT l 7) and 100 % of pigs at PID 21 (GMT l 16), and VN antibody GMT increased 2-to 5-fold post-challenge. The serum VN GMT of group 1, 2 and 3 pigs at PID 21\PCD 0 (40, 
